Skip to content

Source filing unavailable

Q3 2016 · —
Revenue—
Net Income-$6.32Mno prior Q3 2015 on fileN/M vs Q2 2016
EPS Diluted-$23.23no prior Q3 2015 on fileN/M vs Q2 2016
Operating Income-$7,914,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q3 2015 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR